AFLAC Q1 Earnings Announcement Scheduled
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy AFL?
Source: seekingalpha
- Earnings Release Date: AFLAC is set to announce its Q1 earnings on April 29 after market close, with a consensus EPS estimate of $1.80, reflecting an 8.4% year-over-year growth, indicating sustained profitability that could positively impact stock prices.
- Revenue Expectations: The anticipated revenue for Q1 is $4.33 billion, representing a 27.4% year-over-year increase, which highlights the company's strong market performance and may bolster investor confidence, potentially driving stock prices higher.
- Historical Performance: Over the past two years, AFLAC has exceeded EPS and revenue estimates 63% of the time, demonstrating stability and reliability in financial forecasting, which could attract more institutional investor interest.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen five upward and five downward revisions, while revenue estimates experienced one upward revision with no downward adjustments, indicating a cautiously optimistic market outlook on AFLAC's profitability and revenue growth, which may influence future stock price movements.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AFL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AFL
Wall Street analysts forecast AFL stock price to fall
11 Analyst Rating
3 Buy
5 Hold
3 Sell
Hold
Current: 114.680
Low
100.00
Averages
110.90
High
125.00
Current: 114.680
Low
100.00
Averages
110.90
High
125.00
About AFL
Aflac Incorporated provides financial protection to policyholders and customers through its subsidiaries in the United States and Japan. The Company’s principal business is supplemental health and life insurance products. The Company’s segments include Aflac Japan, which includes Aflac Life Insurance Japan (ALIJ), and Aflac U.S., which includes American Family Life Assurance Company of Columbus (Aflac), American Family Life Assurance Company of New York (Aflac New York), Continental American Insurance Company (CAIC), Tier One Insurance Company (TOIC) and Aflac Benefits Solutions, Inc. (ABS). The Aflac Japan segment is the insurer in Japan in terms of cancer and medical (third sector insurance products) policies in force. The Company designs its United States insurance products to provide supplemental coverage for people who already have major medical or primary insurance coverage, as Aflac U.S. insurance policies pay benefits regardless of other insurance.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Earnings Release Date: AFLAC is set to announce its Q1 earnings on April 29 after market close, with a consensus EPS estimate of $1.80, reflecting an 8.4% year-over-year growth, indicating sustained profitability that could positively impact stock prices.
- Revenue Expectations: The anticipated revenue for Q1 is $4.33 billion, representing a 27.4% year-over-year increase, which highlights the company's strong market performance and may bolster investor confidence, potentially driving stock prices higher.
- Historical Performance: Over the past two years, AFLAC has exceeded EPS and revenue estimates 63% of the time, demonstrating stability and reliability in financial forecasting, which could attract more institutional investor interest.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen five upward and five downward revisions, while revenue estimates experienced one upward revision with no downward adjustments, indicating a cautiously optimistic market outlook on AFLAC's profitability and revenue growth, which may influence future stock price movements.
See More
- Strong Market Performance: The S&P 500 and Nasdaq Composite indices reached new all-time highs in April, rising over 8% and 13% respectively, indicating robust market resilience despite ongoing geopolitical tensions and AI disruption concerns, reflecting investor confidence in tech stocks.
- Earnings Pressure on Tech Giants: Next week, five of the 'Magnificent Seven' companies will report earnings, with market expectations for them to demonstrate sufficient revenue growth to justify their high AI expenditures; Alphabet, Amazon, Meta, and Microsoft have all seen stock price increases of over 10% this month, highlighting the market's keen interest in their performance.
- Federal Reserve Meeting Impact: This is expected to be Jerome Powell's last meeting as chair, with the market widely anticipating that the Fed will keep interest rates unchanged, although rising oil prices could complicate future monetary policy, necessitating close attention to how this dynamic may affect the market.
- Cautious Investor Sentiment: As the traditional market adage 'Sell in May' approaches, investors remain wary of potential downside risks, particularly in light of poor software stock performance and rising oil prices, which could further dampen market sentiment.
See More
- Target Price Adjustment: UBS has lowered Aflac's (AFL) price target from $116 to $114 while maintaining a Neutral rating, indicating limited profitability potential amid economic uncertainty and cyclicality.
- Earnings Guidance: During the Q4 2025 earnings call, Aflac executives stated that most of the 2026 guidance remains intact, with underlying earned premiums in Japan expected to decline by 1% to 2%, which could pressure overall revenue.
- US Business Outlook: Aflac anticipates net earned premium growth to remain at the lower end of the 3% to 6% range, with a projected benefit ratio between 48% and 52%, suggesting challenges as the company expands its newer business lines.
- Expense Ratio Forecast: The company expects the expense ratio in the U.S. to range from 36% to 39%, indicating ongoing efforts to optimize its business structure despite economic headwinds to support future growth.
See More

- Market Reactions: The stock market is experiencing a surge due to a cease-fire in Iran, leading to optimism among investors.
- Ongoing Concerns: Despite the positive market response, investors remain wary of underlying issues in the private credit sector.
See More
- Earnings Release Schedule: Aflac plans to release its Q1 2026 financial results after market close on April 29, 2026, providing quarterly earnings and financial supplement materials to ensure timely access to critical information for investors.
- Webcast Conference Call: The company will host a conference call on April 30, 2026, at 8:00 a.m. ET, where CEO Daniel P. Amos and other executives will discuss quarterly results, enhancing transparency and investor confidence.
- Future Earnings Forecast: Aflac has also announced future earnings release dates, with Q2 2026 results set for August 6 and Q3 2026 results on November 4, allowing investors to prepare in advance for upcoming financial disclosures.
- Company Background: As a Fortune 500 company, Aflac has provided financial protection to millions of policyholders for over seven decades, leading the supplemental health insurance market in the U.S. and demonstrating strong corporate responsibility and influence in the insurance industry.
See More
- Reinsurance Agreement: Aflac Re Bermuda Ltd. has entered into a reinsurance agreement with Japan Post Insurance Co., Ltd. involving a block of whole life annuities through coinsurance, marking Aflac's first transaction with an external partner, which is expected to enhance the company's competitive position in the market.
- Strategic Partnership Strengthened: This transaction not only represents the first collaboration between Aflac Re and Japan Post Insurance but also further solidifies their strategic partnership aimed at creating shared value for policyholders and shareholders, thereby improving overall business performance.
- Risk Management Optimization: Aflac Re plans to leverage its expertise to support other Japanese life insurers in reducing risk, enhancing capital management, and expanding new business opportunities, which will contribute to the stability of the entire industry.
- Industry Leadership Reinforced: Aflac's market leadership in both the U.S. and Japan is further solidified, as it remains the largest provider of supplemental health insurance in the U.S. and the leading provider of cancer and medical insurance in Japan, enhancing the company's reputation and market share.
See More










